Hepatoprotective efficacy of ursodeoxycholic acid in pediatrics acute lymphoblastic leukemia.
Pediatr Hematol Oncol
; 29(7): 627-32, 2012 Oct.
Article
en En
| MEDLINE
| ID: mdl-22889151
ABSTRACT
Ursodeoxycholic acid (UDCA) possesses a hepatoprotective effect in drug-induced hepatotoxicity. In a prospective randomized parallel study, 39 children with acute lymphoblastic leukemia (ALL) were randomized to receive UDCA with chemotherapy for 6 months, then discontinued UDCA and were followed up for 3 months, (UDCA group) (N = 19) or receive chemotherapy without UDCA and followed up for 9 months (control group) (N = 20). In this pilot study, UDCA treatment was associated with a trend toward decreased levels of hepatic transaminases when concomitantly administered with chemotherapy and, therefore, safer outcome in children with ALL. Future studies with a larger sample size are needed to confirm the efficacy and safety of UDCA in this setting.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Ácido Ursodesoxicólico
/
Sustancias Protectoras
/
Leucemia-Linfoma Linfoblástico de Células Precursoras
/
Hígado
/
Antineoplásicos
Tipo de estudio:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Child
/
Child, preschool
/
Humans
Idioma:
En
Revista:
Pediatr Hematol Oncol
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2012
Tipo del documento:
Article
País de afiliación:
Egipto